Person

Anne F. Luetkemeyer

0 members

Overview

Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis. During the COVID-19 pandemic Luetkemeyer led a clinical trial of remdesivir. She has also researched treatment of COVID-19 as a co-infection with HIV. Early life and education Luetkemeyer was born in Baltimore, Maryland, to Suzanne Luetkemeyer (née Frey) and John Alexander Luetkemeyer Jr., a commercial real estate developer. She is the youngest of three sisters, one of whom is actress Julie Bowen. She grew up in Ruxton-Riderwood, Maryland. In 1984, Luetkemeyer graduated from the Calvert School. In 1994, Luetkemeyer received an AB with distinction in American Studies from Stanford University. In 1999, she received an M.D. in medicine from Harvard Medical School. In 2002 and 2003, Luetkemeyer trained in internal medicine at the University of California, San Francisco. In 2006, she completed advance training in clinical research there, and then an infectious disease fellowship in 2007. Career In 2012 Luetkemeyer called for investigations into the doses of medications used for the treatment of HIV infection and tuberculosis. The Food and Drug Administration had rewritten the recommendations in 2012. In a series of small studies in Europe it had been shown that rifampicin, a drug used to treat tuberculosis, could limit the effectiveness of efavirenz, a drug used to treat HIV. The drugs interact through a liver enzyme (cytochrome P450) that is produced at elevated levels in patients who take rifampicin, and breaks down the efavirenz. To overcome this, the 2012 FDA recommendations proposed larger doses of efavirenz. Luetkemeyer argued that the recommendations were not appropriate for all populations in the United States, and could result in more drug toxicity. She showed that increasing the dosage of efavirenz may cause more side effects—as well as coming at a greater financial cost.

From Wikipedia (CC BY-SA 4.0).

On IJR

No public IJR answers mention Anne F. Luetkemeyer yet. As people ask about it and share their answers, they'll appear here.

Overview

Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis. During the COVID-19 pandemic Luetkemeyer led a clinical trial of remdesivir. She has also researched treatment of COVID-19 as a co-infection with HIV. Early life and education Luetkemeyer was born in Baltimore, Maryland, to Suzanne Luetkemeyer (née Frey) and John Alexander Luetkemeyer Jr., a commercial real estate developer. She is the youngest of three sisters, one of whom is actress Julie Bowen. She grew up in Ruxton-Riderwood, Maryland. In 1984, Luetkemeyer graduated from the Calvert School. In 1994, Luetkemeyer received an AB with distinction in American Studies from Stanford University. In 1999, she received an M.D. in medicine from Harvard Medical School. In 2002 and 2003, Luetkemeyer trained in internal medicine at the University of California, San Francisco. In 2006, she completed advance training in clinical research there, and then an infectious disease fellowship in 2007. Career In 2012 Luetkemeyer called for investigations into the doses of medications used for the treatment of HIV infection and tuberculosis. The Food and Drug Administration had rewritten the recommendations in 2012. In a series of small studies in Europe it had been shown that rifampicin, a drug used to treat tuberculosis, could limit the effectiveness of efavirenz, a drug used to treat HIV. The drugs interact through a liver enzyme (cytochrome P450) that is produced at elevated levels in patients who take rifampicin, and breaks down the efavirenz. To overcome this, the 2012 FDA recommendations proposed larger doses of efavirenz. Luetkemeyer argued that the recommendations were not appropriate for all populations in the United States, and could result in more drug toxicity. She showed that increasing the dosage of efavirenz may cause more side effects—as well as coming at a greater financial cost.

From Wikipedia (CC BY-SA 4.0).